{
  "CODEINE": {
    "PM": {
      "action": "Avoid codeine — use alternative opioid",
      "alternatives": ["Morphine", "Tramadol", "Oxycodone"],
      "urgency": "immediate",
      "monitoring": "If codeine is used despite genetic findings, monitor for reduced efficacy",
      "references": ["CPIC Codeine Guideline 2021"]
    },
    "IM": {
      "action": "Reduced efficacy — use higher dose or alternative",
      "alternatives": ["Morphine", "Tramadol", "Oxycodone"],
      "urgency": "high",
      "monitoring": "Monitor for adequate pain control; may require dose escalation",
      "references": ["CPIC Codeine Guideline 2021"]
    },
    "NM": {
      "action": "Use standard dosing and monitoring regimen",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Standard pain assessment and side effect monitoring",
      "references": ["CPIC Codeine Guideline 2021"]
    },
    "RM": {
      "action": "Increased toxicity risk — use alternative or reduced dose",
      "alternatives": ["Tramadol", "Morphine (lower dose)", "Non-opioid alternatives"],
      "urgency": "high",
      "monitoring": "Close monitoring for opioid-related side effects; consider lower doses",
      "references": ["CPIC Codeine Guideline 2021"]
    },
    "URM": {
      "action": "Avoid codeine — high toxicity risk — use alternative",
      "alternatives": ["Tramadol", "Morphine (much lower dose)", "Non-opioid alternatives"],
      "urgency": "immediate",
      "monitoring": "If codeine is used, monitor closely for toxicity",
      "references": ["CPIC Codeine Guideline 2021"]
    }
  },
  "WARFARIN": {
    "PM": {
      "action": "Use significantly reduced dose; may require 10-20% of standard dose",
      "alternatives": ["Consider direct oral anticoagulants (DOACs): dabigatran, rivaroxaban, apixaban"],
      "urgency": "immediate",
      "monitoring": "Check INR within 3 days of initiation; then every 2-3 days; adjust dose based on INR response",
      "references": ["CPIC Warfarin-CYP2C9-VKORC1 Guideline 2017"]
    },
    "IM": {
      "action": "Use reduced dose; typically 30-50% of standard dose initially",
      "alternatives": ["Consider DOACs if suitable"],
      "urgency": "high",
      "monitoring": "Check INR within 3 days; then 1-2 times per week until stable",
      "references": ["CPIC Warfarin-CYP2C9-VKORC1 Guideline 2017"]
    },
    "NM": {
      "action": "Use standard dosing (5 mg daily); adjust based on INR response",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Check INR on Day 3-4, then every 2-4 weeks when stable (INR 2-3)",
      "references": ["CPIC Warfarin-CYP2C9-VKORC1 Guideline 2017"]
    },
    "RM": {
      "action": "May require higher dose; typically 1.5-2x standard dose",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Standard INR monitoring schedule; may need higher maintenance doses",
      "references": ["CPIC Warfarin-CYP2C9-VKORC1 Guideline 2017"]
    },
    "URM": {
      "action": "May require substantially higher dose (often 2-3x standard)",
      "alternatives": ["Consider higher-intensity anticoagulation if clinically needed"],
      "urgency": "normal",
      "monitoring": "Standard INR monitoring; ensure adequate anticoagulation achieved",
      "references": ["CPIC Warfarin-CYP2C9-VKORC1 Guideline 2017"]
    }
  },
  "CLOPIDOGREL": {
    "PM": {
      "action": "Avoid clopidogrel; use alternative P2Y12 inhibitor",
      "alternatives": ["Prasugrel (5-10 mg daily)", "Ticagrelor (60 mg daily)", "Cilostazol"],
      "urgency": "immediate",
      "monitoring": "If clopidogrel is used despite genetic findings, monitor for recurrent stent thrombosis",
      "references": ["CPIC Clopidogrel-CYP2C19 Guideline 2017", "FDA Black Box Warning"]
    },
    "IM": {
      "action": "Consider alternative P2Y12 inhibitor or high-dose clopidogrel with additional monitoring",
      "alternatives": ["Prasugrel (5-10 mg daily)", "Ticagrelor (60 mg daily)"],
      "urgency": "high",
      "monitoring": "If clopidogrel used: assess for stent thrombosis, recurrent events; consider platelet function testing",
      "references": ["CPIC Clopidogrel-CYP2C19 Guideline 2017"]
    },
    "NM": {
      "action": "Use standard dose (300-600 mg loading dose, then 75 mg daily)",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Standard cardiovascular event monitoring",
      "references": ["CPIC Clopidogrel-CYP2C19 Guideline 2017"]
    },
    "RM": {
      "action": "Standard dose acceptable; may assess for excessive bleeding risk",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Monitor for excessive bleeding; may reduce dose if high bleeding risk",
      "references": ["CPIC Clopidogrel-CYP2C19 Guideline 2017"]
    },
    "URM": {
      "action": "Standard dose acceptable; monitor for increased bleeding",
      "alternatives": ["Consider dose reduction if significant bleeding occurs"],
      "urgency": "normal",
      "monitoring": "Assess for increased bleeding complications",
      "references": ["CPIC Clopidogrel-CYP2C19 Guideline 2017"]
    }
  },
  "SIMVASTATIN": {
    "PM": {
      "action": "Avoid simvastatin; use alternative statin",
      "alternatives": ["Rosuvastatin", "Pravastatin", "Fluvastatin", "Pitavastatin"],
      "urgency": "high",
      "monitoring": "Monitor CK if simvastatin is used despite genetic findings",
      "references": ["CPIC Simvastatin-SLCO1B1 Guideline 2012"]
    },
    "IM": {
      "action": "Use reduced dose (10-20 mg daily maximum) or alternative statin",
      "alternatives": ["Rosuvastatin", "Pravastatin", "Fluvastatin"],
      "urgency": "high",
      "monitoring": "Monitor for myopathy symptoms; check CK if symptoms develop",
      "references": ["CPIC Simvastatin-SLCO1B1 Guideline 2012"]
    },
    "NM": {
      "action": "Use standard dosing (20-40 mg daily)",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Standard statin monitoring; baseline and periodic CK if symptoms develop",
      "references": ["CPIC Simvastatin-SLCO1B1 Guideline 2012"]
    },
    "RM": {
      "action": "Standard dosing; may require higher doses for LDL goals",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Monitor LDL achievement; standard safety monitoring",
      "references": ["CPIC Simvastatin-SLCO1B1 Guideline 2012"]
    },
    "URM": {
      "action": "Standard dosing; may require higher doses for LDL goals",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Ensure adequate LDL reduction at assigned dose",
      "references": ["CPIC Simvastatin-SLCO1B1 Guideline 2012"]
    }
  },
  "AZATHIOPRINE": {
    "PM": {
      "action": "Avoid azathioprine; use alternative immunosuppressant",
      "alternatives": ["Mycophenolate mofetil (MMF)", "Calcineurin inhibitors (tacrolimus, cyclosporine)", "Corticosteroids"],
      "urgency": "immediate",
      "monitoring": "Do not use azathioprine; severe bone marrow failure will occur",
      "references": ["CPIC Azathioprine-TPMT Guideline 2022"]
    },
    "IM": {
      "action": "Use significantly reduced dose (50% or less of standard dose)",
      "alternatives": ["Mycophenolate mofetil", "Calcineurin inhibitors"],
      "urgency": "high",
      "monitoring": "Baseline CBC; monitor CBC at 2 weeks, monthly for 3 months, then every 3 months minimum",
      "references": ["CPIC Azathioprine-TPMT Guideline 2022"]
    },
    "NM": {
      "action": "Use standard dose; detailed CBC monitoring recommended",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Baseline CBC; then monthly for 3 months, then every 3 months",
      "references": ["CPIC Azathioprine-TPMT Guideline 2022"]
    },
    "RM": {
      "action": "Standard to higher dose may be needed for therapeutic effect",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Standard CBC monitoring; assess for adequate immunosuppression",
      "references": ["CPIC Azathioprine-TPMT Guideline 2022"]
    },
    "URM": {
      "action": "Standard dose; may require higher doses if needed therapeutically",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Standard monitoring; ensure adequate immunosuppressive response",
      "references": ["CPIC Azathioprine-TPMT Guideline 2022"]
    }
  },
  "FLUOROURACIL": {
    "PM": {
      "action": "Avoid 5-FU; use alternative chemotherapy regimen",
      "alternatives": ["Capecitabine (caution—also requires DPYD)", "Taxanes", "Alternative cancer-specific regimens"],
      "urgency": "immediate",
      "monitoring": "Do not use 5-FU; severe, potentially fatal toxicity will occur",
      "references": ["CPIC Fluorouracil-DPYD Guideline 2018", "FDA Black Box Warning"]
    },
    "IM": {
      "action": "Use significantly reduced dose (25-50% of standard dose)",
      "alternatives": ["Capecitabine (caution—also DPYD-dependent)", "Taxanes", "Alternative regimens"],
      "urgency": "immediate",
      "monitoring": "Baseline CBC; CBC monitoring days 5, 10, 14 after each cycle; monitor for toxicity daily during cycle",
      "references": ["CPIC Fluorouracil-DPYD Guideline 2018"]
    },
    "NM": {
      "action": "Use standard dose with standard monitoring",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Standard CBC and clinical monitoring per protocol",
      "references": ["CPIC Fluorouracil-DPYD Guideline 2018"]
    },
    "RM": {
      "action": "Use standard or higher dose if needed for therapeutic goal",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Standard monitoring; ensure adequate chemotherapy response",
      "references": ["CPIC Fluorouracil-DPYD Guideline 2018"]
    },
    "URM": {
      "action": "Standard dose; may require higher doses if needed for therapeutic response",
      "alternatives": [],
      "urgency": "normal",
      "monitoring": "Standard monitoring; ensure adequate drug exposure for cancer control",
      "references": ["CPIC Fluorouracil-DPYD Guideline 2018"]
    }
  }
}
